YAP–NF-κB–NLRP3 Control of UC Pyroptosis

Study Background and Research Question

Ulcerative colitis (UC) is characterized by chronic inflammation of the colonic mucosa, epithelial barrier disruption, and dysregulated innate and adaptive immune activity. Although several biologic therapies can reduce inflammation, incomplete responses and acquired treatment resistance remain important clinical problems. A clearer understanding of how epithelial injury is initiated could therefore support more precise approaches to mucosal healing.

Pyroptosis is particularly relevant to this question because it couples programmed cell death with release of inflammatory mediators. In the canonical inflammasome pathway, activation of caspase-1 promotes maturation of interleukin-1β and interleukin-18 and cleaves gasdermin D (GSDMD). The resulting GSDMD amino-terminal fragment forms membrane pores, allowing cytokine release and eventual lytic cell death. The reference study, YAP inactivated by NF-κB p65, can protect against colonic epithelial cell pyroptosis in ulcerative colitis via transcriptionally regulating NLRP3, addresses how this inflammatory death program is controlled in colonic epithelial cells.

The central research question was whether Yes-associated protein (YAP), a major transcriptional effector of the Hippo pathway, suppresses pyroptosis in UC and, if so, how inflammatory signaling disables that protection. The authors focused on the relationship among YAP, NF-κB p65, LATS1, NLRP3, and GSDMD. This framing is important because YAP is often discussed in tissue regeneration, whereas NF-κB and NLRP3 are more commonly studied as inflammatory mediators. The study tests whether these systems form a functional pathway rather than acting as independent responses.

Key Innovation from the Reference Study

The main innovation is the identification of YAP as a transcriptional brake on NLRP3-associated pyroptosis in the colonic epithelium. According to the reference study, YAP associates with the NLRP3 promoter and represses its transcription. When YAP is overexpressed, pyroptotic responses in FHC colonic epithelial cells are reduced. Conversely, inflammatory activation of NF-κB p65 increases LATS1-dependent YAP phosphorylation, which limits YAP nuclear activity and lowers its effective expression.

This model places the pathway in a defined order: NF-κB p65 activation is upstream of LATS1-mediated YAP inactivation; reduced YAP activity weakens transcriptional repression at the NLRP3 promoter; increased NLRP3 signaling then contributes to GSDMD-dependent pyroptosis. The work therefore extends the interpretation of NF-κB signaling beyond direct inflammatory gene activation and presents it as a regulator of epithelial cell-death susceptibility through Hippo-pathway control.

A second important contribution is the use of GSDMD loss-of-function evidence to position pyroptosis within the pathway. GSDMD deficiency markedly attenuated DSS-induced colitis in mice, while additional YAP overexpression did not further improve inflammation in GSDMD-knockout animals. This epistasis-like result supports the view that YAP acts substantially through a GSDMD-dependent pyroptotic route, rather than simply producing a parallel anti-inflammatory effect.

Methods and Experimental Design Insights

The experimental design combines a reductionist epithelial-cell model, genetically defined mouse experiments, and mechanism-oriented molecular assays. This combination is useful because each component answers a different question: whether the phenotype occurs in epithelial cells, whether GSDMD is required in vivo, and how YAP is connected to NLRP3 transcription.

Protocol Parameters

• Cellular pyroptosis model: FHC colonic epithelial cells were treated with LPS plus ATP to induce an inflammatory pyroptosis model. This system is appropriate for examining cell-intrinsic signaling but should not be interpreted as a complete reconstruction of the UC microenvironment.
• Animal disease model: DSS-induced colitis was evaluated in wild-type and GSDMD-knockout mice. The genotype comparison provides a direct test of whether GSDMD-mediated cell death contributes to colonic inflammation.
• YAP perturbation: YAP-overexpression lentiviral approaches were used in FHC cells and delivered intraperitoneally in mice. These gain-of-function experiments test whether increasing YAP activity is sufficient to reduce pyroptotic or inflammatory outcomes.
• Subcellular localization: Nucleoplasmic separation was used to assess the distribution of YAP between nuclear and non-nuclear compartments, a relevant readout because transcriptional regulation by YAP depends on its nuclear availability.
• Chromatin mechanism: Chromatin immunoprecipitation was used to investigate YAP association with the NLRP3 promoter. In combination with expression and phenotype measurements, this assay supports a transcriptional mechanism rather than a purely indirect correlation.

The study design also illustrates the value of combining gain- and loss-of-function experiments. YAP overexpression tests protection, whereas GSDMD deletion tests pathway dependence. The two interventions are not interchangeable: YAP manipulation addresses regulation upstream of pyroptosis, while GSDMD deletion removes a terminal execution component. Interpreting their effects together is what gives the proposed pathway greater mechanistic coherence.

Core Findings and Why They Matter

The reference study reports that GSDMD-related pyroptosis is elevated in samples from patients with UC and in DSS-treated colitis mice. This observation links the experimental models to a disease-associated inflammatory phenotype, although it does not by itself establish whether pyroptosis initiates or amplifies every stage of human UC. The protective effect of GSDMD knockout in DSS-treated mice provides stronger causal evidence that this death pathway contributes to tissue inflammation in the model.

In FHC cells, increased YAP expression inhibited pyroptosis. Mechanistically, the authors found that YAP can bind the NLRP3 promoter and repress its transcription. This finding is significant because it assigns YAP a direct regulatory position at an inflammasome-related gene, rather than treating YAP only as a general determinant of epithelial proliferation or regeneration.

The upstream component of the model involves NF-κB p65. The study found that p65 was increased under pyroptotic conditions and promoted YAP phosphorylation through LATS1. Phosphorylated YAP showed reduced nuclear translocation and lower effective expression, weakening its ability to repress NLRP3. In this interpretation, inflammatory NF-κB activation removes a transcriptional constraint on inflammasome-related signaling.

The in vivo interaction between YAP and GSDMD further strengthens this conclusion. YAP overexpression improved inflammatory outcomes in settings where GSDMD-mediated pyroptosis was intact, but did not produce an additional improvement in GSDMD-knockout mice. This result is consistent with YAP functioning upstream of, or within, the GSDMD-dependent branch of the response. It does not prove that all YAP effects in the colon are mediated by pyroptosis, but it narrows the mechanism relevant to the experimental phenotype.

Collectively, the findings propose an epithelial regulatory circuit: NF-κB p65 increases LATS1-dependent YAP inactivation; inactive YAP releases repression of NLRP3; and enhanced NLRP3 activity contributes to GSDMD-associated pyroptosis. The practical scientific value of this model is that it links inflammatory transcription, Hippo signaling, inflammasome regulation, and epithelial cell death in one testable framework.

Comparison with Existing Internal Articles

The internal article CSRP2 Modulates PDGFRA/PI3K/AKT Signaling in Mesenchymal Glioma examines a different disease context and a different signaling output. That study emphasizes CSRP2, PRC1-associated epigenetic regulation, and PDGFRA/PI3K/AKT signaling in glioma aggressiveness, whereas the reference UC study centers on YAP transcriptional control of NLRP3 and GSDMD-mediated pyroptosis. The relationship is methodological rather than mechanistic: both studies use an upstream regulatory factor to explain how disease-associated signaling programs are established, but the glioma findings should not be used as evidence for the YAP–NLRP3 axis in colitis. This distinction helps preserve tissue and disease specificity when comparing signaling literature.

Limitations and Transferability

Several limitations affect how broadly the findings can be transferred. The LPS-plus-ATP FHC model is experimentally tractable but represents only selected features of epithelial pyroptosis. It does not reproduce the full cellular, microbial, vascular, and matrix environment of the human colon. Similarly, DSS-induced colitis is valuable for studying barrier injury and inflammation but is not identical to the heterogeneous causes and clinical courses of UC.

The YAP experiments rely on overexpression, including lentiviral delivery in cells and intraperitoneal administration in mice. Such approaches establish biological sufficiency but may produce expression levels, tissue distribution, or timing that differ from endogenous regulation. Future validation should therefore examine endogenous YAP activity in relevant epithelial populations and determine whether the proposed NF-κB p65–LATS1 relationship is maintained across disease stages.

The chromatin data support YAP occupancy at the NLRP3 promoter and the functional data support transcriptional repression, but additional work would be needed to define the complete transcriptional complex and the precise requirements for repression. The study also does not establish that manipulating this pathway will be safe or effective therapeutically in patients. YAP has broader roles in epithelial repair and tissue homeostasis, so pathway intervention could have effects beyond pyroptosis. These considerations make the findings a strong mechanistic basis for further study, not a clinical treatment recommendation.

Research Support Resources

Protein-level validation of YAP phosphorylation, NF-κB p65, NLRP3, and GSDMD requires careful handling of disrupted cells and tissues. Researchers can use the Protease Inhibitor Cocktail (EDTA-Free, 100X in DMSO) (SKU K1007) to support similar protein extraction workflows. As a protein extraction protease inhibitor, it is intended for protease inhibition in cell lysates and provides inhibition of serine and cysteine proteases, among other protease classes. Its EDTA-free formulation can also be considered when a phosphorylation analysis compatible inhibitor cocktail is preferred or when divalent-cation-sensitive enzyme assays are planned. This reagent supports sample preservation; it does not replace the biological controls or mechanistic experiments required to test the YAP–NF-κB–NLRP3 model.